ADS AIPHIA Development Services AG Report issue

For profit Phase 2
Founded: Pfäffikon Switzerland (2012)

Organization Overview

First Clinical Trial
2020
NCT04311489
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ADS AIPHIA Development Services AG | ADS Therapeutics, LLC

Active Ingredients

Drugs in Phase 2 Trials (2)

cyclodextrin (1 trial)

urodilatin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ascites (Phase 2)

Fibrosis (Phase 2)

Liver Cirrhosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2